Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dystrophic epidermolysis bullosa (DEB) pruriginosa is a rare subtype of DEB characterized by multiple, violaceous, and severe pruritic lichenified nodules along with blisters. Here, we report the case of a Korean male who, since the age of 3 years, had multiple pruritic nodules with blisters on both lower extremities. Genetic testing is required to diagnose DEB pruriginosa because its clinical and histologic features are inconclusive. We identified compound heterozygous variants of c.5797C>T (p.R1933*) and c.3301C>T (p.R1101W) in the patient, leading to a diagnosis of recessive DEB pruriginosa. Among the variants identified, c.3301C>T is a novel missense variant that has not been reported previously. This variant is in exon 26, which encodes von Willebrand factor A (vWFA) in collagen type VII. vWFA is known to preserve normal dermal structures by interacting with dermal collagens and basement membranes. Considering that this variant contradicts the general concept that autosomal dominant inheritance is more common and that variants typically occur in the triple helical collagenous domain of in DEB pruriginosa, we focus on the rarity of this case and the possible pathogenic role of the c.3301C>T (p.R1101W) variant.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10727861PMC
http://dx.doi.org/10.5021/ad.21.176DOI Listing

Publication Analysis

Top Keywords

deb pruriginosa
16
c3301c>t pr1101w
12
missense variant
8
von willebrand
8
willebrand factor
8
dystrophic epidermolysis
8
epidermolysis bullosa
8
compound heterozygous
8
heterozygous variants
8
nodules blisters
8

Similar Publications

Dystrophic epidermolysis bullosa (DEB) is a genetic skin disease with limited therapeutic options for managing pruritus. This study retrospectively evaluated the efficacy and safety of Dupilumab monotherapy in patients with DEB suffering from severe pruritus. DEB patients treated with Dupilumab between June 2021 and June 2023 were reviewed.

View Article and Find Full Text PDF

Epidermolysis bullosa pruriginosa (EBP) is a rare subtype of dystrophic epidermolysis bullosa (DEB) that poses significant management challenges. In this case report, a 12-year-old female with EBP was successfully treated with upadacitinib at a dosage of 15 mg once daily for a period of 12 weeks, after which the frequency was changed to every other day. A review of the literature identified 19 cases successfully treated with a Janus kinase inhibitor (JAKi) suggesting that JAKis are a promising option for EBP patients.

View Article and Find Full Text PDF

Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.

Adv Skin Wound Care

February 2024

At the Xi'an Jiaotong University and Second Affiliated Hospital, Shaanxi, China, Dan-Yang Yang, MM, Wen-Wen Jing, BM, and Xin Liu, BM, are Medical Students; Li Li, MM, and Tao Lu, MM, are Doctors; and Xiao-Li Li, PhD, is Associate Professor.

Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of dystrophic epidermolysis bullosa, and traditional treatments have limited efficacy. Dupilumab has demonstrated remarkable efficacy in relieving pruritus. In this case study, after traditional treatment failed, providers recommended the patient begin dupilumab to treat his pruritus.

View Article and Find Full Text PDF

Refractory pruritus is the most distressing, disease-related symptom in patients with dystrophic epidermolysis bullosa (DEB), inducing an itch-scratch-blister cycle. Chronic inflammation is a hallmark of DEB, thus upregulation of inflammatory cytokines and Janus kinase (JAK) signaling may play a role in DEB-related pruritus. We retrospectively reviewed the medical records of DEB patients with refractory pruritus who were treated with either baricitinib, a JAK1/2 inhibitor, or upadacitinib, a selective JAK1 inhibitor.

View Article and Find Full Text PDF

Dystrophic epidermolysis bullosa (DEB) pruriginosa is a rare subtype of DEB characterized by multiple, violaceous, and severe pruritic lichenified nodules along with blisters. Here, we report the case of a Korean male who, since the age of 3 years, had multiple pruritic nodules with blisters on both lower extremities. Genetic testing is required to diagnose DEB pruriginosa because its clinical and histologic features are inconclusive.

View Article and Find Full Text PDF